Back to search results

Observational Study of Compl-AI for Opioid Use Disorder Treatment

This study is looking at whether a tool called Compl-AI can accurately predict if adults receiving real-world treatment for opioid use disorder (OUD) will stop their medication early. All participants will continue to receive their usual medication for opioid use disorder (MOUD) as part of their routine care. Researchers will observe how you engage with your treatment for three months and see how well Compl-AI predicts your outcomes. You can join if you are 18 or older, have OUD, and are receiving or eligible for MOUD. The study aims to see if Compl-AI can accurately predict early discontinuation of MOUD.

Study design
This is an observational study with an estimated 295 participants. There are no comparison groups, meaning everyone receives their usual care.
What's involved
You will complete 4 visits, including a questionnaire about personal experiences, substance use, and treatment history during the first visit. Your treatment engagement will be observed for three months.
Compensation
Not stated in the trial record.
Follow-up
Your medication visits and doses taken will be measured for three months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07456930

Real-World Evaluation of Compl-AI for Predicting Early Medication Dropout in Opioid Use Disorder Treatment

Not Yet Recruiting
Not specifiedAges 18+Observational
Tools4Patient
~295 participants
Updated 2026-03-18 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of attended MOUD medication visits
Measured over Observation period will be three (3) months.
+1 more outcome measured

Conditions

Opioid Use Disorder

Explore related trials

Opioid Use Disorder

Where it's being run

2 sites across 1 states
California2

Who to contact

Chantal Gossuin
[email protected]
+32(0)71140200
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability to understand and provide written informed consent.
Male and female participant 18 years of age at the time of consent.
Participant with OUD based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V).
Eligible to receive MOUD per site standard of care or currently receiving MOUD initiated prior to study enrollment.

Exclusion

Cognitive impairment that precludes the ability to provide written informed consent.
Already enrolled in another study/program.

What this trial measures

  • Proportion of attended MOUD medication visitsObservation period will be three (3) months.
  • Proportion of prescribed doses takenObservation period will be three (3) months.